Despite their enormous disease burden, respiratory illnesses such as COPD and asthma receive little attention in research, policy, and public discourse. An international group of early career scientists is now calling for greater visibility, national...
Dr. Andrew Tony-Odigie, a scientist at the DZL Academy based at TLRC, has been awarded the Adolf Windorfer Prize 2025 together with his team. The research group demonstrated how beneficial bacteria can inhibit the growth...
Bronchiectasis is a chronic lung disease marked by recurring infections and a gradual decline in lung function. Despite its impact on quality of life, treatment options have remained limited. New research findings now point to...
DZL researchers have succeeded in confirming the long-term effects of dual therapy with Lumacaftor/Ivacaftor in toddlers with cystic fibrosis. Early treatment initiation significantly reduces the progression of cystic fibrosis.
A team led by DZL researchers Dr. Anita Balázs and Dr. Frauke Stanke has received a €19,000 grant from the German Cystic Fibrosis Association (Mukoviszidose e.V.). The research group is investigating the role of the...
The research team led by Dr. Andrew Tony-Odigie at Heidelberg University Hospital has received €148,330 in funding to investigate the role of commensal bacteria in CFTR modulator therapy for cystic fibrosis and to develop new...
Cystic fibrosis is an incurable genetic disease that causes thick lung mucus and impairs lung function. Triple therapy addresses the underlying defect and is now approved for use in children. A recent study demonstrates significant...
The frequency and significance of bronchiectasis disease were greatly underestimated until a few years ago.
Seventy doctors and scientists from 24 countries discussed the latest developments in the diagnosis and treatment of cystic fibrosis at the annual meeting of the Diagnostic Network Working Group (DNWG) of the European Cystic Fibrosis...
Treatment with the CFTR modulators elexacaftor, tezacaftor and ivacaftor improves the innate defenses in the nasal mucosa and reduces inflammatory reactions in children with cystic fibrosis. This was shown by researchers at the Charité -...
Good news for cystic fibrosis patients: The interim analysis of the first long-term study shows that the therapy with the three CFTR modulators Elexacaftor, Tezacaftor, and Ivacaftor is effective, safe, and well-tolerated in the long...
DZL scientists have studied the airways of patients with cystic fibrosis and analysed the genetic information of all microorganisms living there.
